改良版预处理方案的自体造血干细胞移植治疗急性髓系白血病3例临床观察及文献复习

Clinical observation and literature review of three cases of acute myeloid leukemia treated by autologous hematopoietic stem cell transplantation with modified preconditioning protocol

目的 分析克拉屈滨(CLAD)联合阿糖胞苷及白消安+环磷酰胺(BuCy)的预处理方案对急性髓系白血病患者进行自体造血干细胞移植的疗效及生存影响。方法 选取完全缓解且残留病灶阴性的急性髓系白血病患者,采用CLAD联合阿糖胞苷及BuCy的预处理方案进行自体造血干细胞移植,观察疗效、移植并发症及预后情况。结果 3例患者移植并发症轻,造血重建时间早。3例患者无疾病进展时间分别为25、20、12个月,目前仍无复发。结论 对于成人急性髓系白血病患者,采用CLAD联合阿糖胞苷的预处理方案,可促进植入,降低复发率,改善患者总体生存质量。

Objective To investigate the efficacy and survival effects of cladribine(CLAD)combined with cytarabine and BuCy pretreatment regimen on autologous hematopoietic stem cell transplantation in patients with acute myeloid leukemia.Methods Patients with acute myeloid leukemia with complete remission and negative residual lesions were selected for autologous hematopoietic stem cell transplantation using CLAD combined with cytarabine and BuCy pretreatment regimen,and the therapeutic effect,transplantation complications and prognosis were observed.Results The transplantation complications of three patients were mild and the hematopoietic reconstruction time was early.The continuous remission time of three patients was 25,20,12 months,respectively,and there was still no recurrence.Conclusion For adult patients with acute myeloid leukemia,CLAD combined with cytarabine and BuCy pretreatment regimen can promote implantation,reduce recurrence rate,and improve the overall quality of life of patients.